Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Verra Therapeutics General Information
Verra Therapeutics develops novel small protein drugs that inhibit disease-driving regulatory proteases. Their lead candidate, VTH245, has shown efficacy in animal models for reducing mucus overproduction and lung damage in COPD. The company’s approach adapts nature’s evolved inhibitor sequences for each target. VTH245 demonstrates favorable pharmacokinetics, compatibility with subcutaneous/inhaled administration, good tolerability in toxicity studies, and potential suitability for chronic use.
Contact Information
Primary Industry
Biotech
Corporate Office
Near Ithaca / Ithaca area, New York
United States
United States
Drug Pipeline
VTH144
Pre-clinicalKey Partnerships
Verra Therapeutics Funding
No funding data available
To view Verra Therapeutics's complete valuation and funding history, request access »